"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
| Descriptor ID |
D002047
|
| MeSH Number(s) |
D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
|
| Concept/Terms |
Subutex- Subutex
- Buprex
- Temgesic
- Temgésic
6029-M- 6029-M
- 6029 M
- 6029M
- RX-6029-M
- RX 6029 M
- RX6029M
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine".
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".
This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 2 | 4 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 1 | 3 |
| 2001 | 2 | 1 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 3 | 4 | 7 |
| 2019 | 1 | 0 | 1 |
| 2020 | 4 | 1 | 5 |
| 2021 | 7 | 0 | 7 |
| 2022 | 6 | 0 | 6 |
| 2023 | 7 | 1 | 8 |
| 2024 | 3 | 2 | 5 |
| 2025 | 6 | 2 | 8 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Buprenorphine" by people in Profiles.
-
Predictors of incident anxiety and stress-related diagnoses following buprenorphine initiation among commercially insured patients with opioid use disorder. Drug Alcohol Depend. 2026 Oct 01; 287:113301.
-
An Examination of Buprenorphine and Norbuprenorphine Concentrations in Inpatients Receiving Medications for Opioid Use Disorder. J Appl Lab Med. 2026 Jul 01; 11(4):735-747.
-
Training in medications for opioid use disorder and buprenorphine prescribing in the post X-waiver era: Insights from a nationwide, multispecialty survey. Prev Med. 2026 02; 203:108485.
-
Cost-Effectiveness of Treatment for Opioid Use Disorder in Pregnancy and Its Impact on Birth Outcomes. JAMA Pediatr. 2025 Nov 01; 179(11):1203-1216.
-
Gaps in buprenorphine access: Examining provider availability and treatment continuity. J Subst Use Addict Treat. 2026 01; 180:209818.
-
Telehealth Buprenorphine Initiation for Opioid Use Disorder Among American Indian and Alaska Native Veterans, April 2017-March 2023. Telemed J E Health. 2025 Nov; 31(11):1333-1341.
-
Disparities in Treatment and Referral After an Opioid Overdose Among Emergency Department Patients. JAMA Netw Open. 2025 07 01; 8(7):e2518569.
-
Association between buprenorphine adherence for opioid use disorder and clinical events and healthcare spending among older patients. J Subst Use Addict Treat. 2025 09; 176:209740.
-
Buprenorphine Treatment in Pregnancy and Maternal-Infant Outcomes. JAMA Health Forum. 2025 04 27; 6(4.11):e251814.
-
Concurrent Depression Management in Patients with Opioid Use Disorder Undergoing Buprenorphine Therapy: Association with Buprenorphine Discontinuation. J Dual Diagn. 2025 Apr; 21(2):142-151.